Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: a prospective clinical trial

References

• Frydman R., Parncix I., Belaisch Allart J., Fornian R., Hazout A., Fernandez A., Testart J. LHRH agonists in IVF: different methods of utilization and comparison with previous ovulation stimulation treatments. Hum. Reprod. 1988; 3: 559–61
   PubMed Web of Science ®Google Scholar
• Neveu S., Hedon B., Bringer J., Chinchole J. M., Arnal F., Humeau C. Ovarian stimulation by a combination of a GnRH-a and gonadotropins for in vitro fertilization. Fertil. Steril. 1987; 47: 639–43
   PubMed Web of Science ®Google Scholar
• Martin M. C., Givens C. R., Schriock E. D., Glass R. H., Dandekar P. V. The choice of a gonadotropin-releasing hormone analog influences outcome of in vitro fertilization treatment. Am. J. Obstet. Cynecol. 1994; 170: 1629–34
   PubMed Web of Science ®Google Scholar
• Penzias A. S., Shamma F. N., Gutmann J. N., Jones E. E., DeCherney A. H., Lavy G. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial. Obstet. Gynecol. 1992; 79: 739–42
   Google Scholar
• Burry K. A. Nafarelin in the management of endometriosis: quality of life assessment. Am. J. Obstet. Gynecol. 1992; 166: 735–9
   PubMedGoogle Scholar
• Nestor J. J. Development of agonistic LHRH analogues. LHRH and Its Analogues: Contraceptive and Therapeutic Applications, B. H. Vickery, J. J. Nestor, E. S. E. Hafez. Kluwer Academic Press, Dordrecht, Boston and London 1984; 3–10
   Google Scholar
• Fisch B., Kaplan-Kraicer R., Amit S., Ovadia J., Tadir Y. The effect of preinsemination interval upon fertilization of human oocytes. in vitro. Hum. Reprod. 1989; 4: 954–6
   PubMed Web of Science ®Google Scholar
• Dodson W. C. Role of gonadotropinreleasing hormone agonists in ovulation induction. J. Reprod. Med. 1989; 34: 76–80
   Google Scholar
• Hughes E. G., King C., Wood E. C. A prospective study of prognostic factors in vitro fertilization and embryo transfer. Fertil. Steril. 1989; 51: 838–44
   PubMed Web of Science ®Google Scholar
• Yen S. S. C. Clinical applications of gonadotropin-releasing hormone and gonadotropin-releasing hormone analogs. Fertil. Steril. 1983; 39: 257–66
   PubMed Web of Science ®Google Scholar
• MacLachlan V., Besanko M., O'Shea F., Wade H., Wood C., Trounson A., Healy D. L. A controlled study of luteinizing hormone-releasing hormone agonist (Buserelin) for the induction of folliculogenesis before in vitro fertilization. N. Engl. J. Med. 1989; 320: 1233–7
   Google Scholar
• Hughes E. G., Fedorkow D. M., Daya S., Sagle M. A., Van de Koppel P., Collins J. A. The routine use of gonadotropin-releasing hormone agonists prior to in vitro fertilization and gamete intrafallopian transfer: a meta-analysis of randomized controlled trials. Fertil. Steril. 1992; 58: 888–96
   PubMed Web of Science ®Google Scholar
• Loumaye E., Vankrieken L., Depreester S., Psalti I., De Cooman S., Thomas K. Hormonal changes induced by short term administration of a gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development. Fertil. Steril. 1989; 51: 105–11
   PubMed Web of Science ®Google Scholar
• Pace J., Miller Land J., Rose L. I. GnRH agonists: gonadotrelin, leuprolide and Nafarelin. AFP Clin. Pharmacol. 1991; 44: 1777–83
   Google Scholar
• Chaplin M. D. Bioavailabilty of Nafarelin in healthy volunteers. Am. J. Obstet. Gynecol. 1992; 166: 762–5
   PubMed Web of Science ®Google Scholar
• Henzl M. R. Gonadotropin-releasing hormone analogs: update on new findings. Am. J. Obstet. Gynecol. 1992; 166: 757–61
   Google Scholar
• Chan R. L., Henzl M. R., LePage M. E., LaFargue J., Nerenberg C. A., Anik S., Chaplin M. D. Absorption and metabolism of Nafarelin, a potent agonist of gonadotropinreleasing hormone. Clin. Pharmacoi. Ther. 1988; 44: 275–82
   PubMed Web of Science ®Google Scholar
• Ron-El R., Herman A., Golan A., Nachum H., Soffer Y., Caspi E. Gonadotropins and combined gonadotropin-releasing hormone agonist—gonadotropins protocols in a randomized prospective study. Fertil. Steril. 1991; 55: 574–8
   Google Scholar
• Dantas Z. N., Vicino M., Balmaceda J. P., Asch R. H., Stone S. C. Comparison between Nafarelin and leuprolide acetate for in vitro fertilization: preliminary clinical study. Fertil. Steril. 1994; 61: 705–8
   Google Scholar
• Schmidt Sarosi C. L., Yerovi L. A., Jr. The efficacy of Nafarelin acetate versus leuprolide acetate in conjunction with human menopausal gonadotropins for superovulation/intrauterine insemination. Int. J. Fertil. Menopausal Stud. 1994; 39: 20–5
   Google Scholar
• Goldman J. A., Dicker D., Feldberg D., Ashkenazi J., Voliowich I. A prospective randomized comparison of two gonadotropinreleasing hormone agonists, Nafarelin acetate and Buserelin acetate, in in vitro fertilization-embryo transfer. Hum. Reprod. 1994; 9: 226–8
   PubMedGoogle Scholar
• Navot D., Rosenwaks Z., Anderson F., Hodgen G. D. Gonadotropin-releasing hormone agonist-induced ovarian hyperstimulation: low-dose side effects in women and dose side effects in women and monkeys. Fertil. Steril. 1991; 55: 1069–75
   PubMedGoogle Scholar
• Lydic M. L., Jacobs S. L. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: a randomized clinical trial [letter]. Obstet. Gynecol. 1992; 80: 727–9
   Google Scholar
• Silverberg K. M., Burns W. N., Olive D. L., Riehl R. M., Schenken R. S. Serum progesterone levels predict success of in vitro fertilization/embryo transfer in patients stimulated with leuprolide acetate and human menopausal gonadotropins. J. Clin. Endocrinol. Metab. 1991; 73: 797–803
   PubMed Web of Science ®Google Scholar
• Fanchin R., De Zeigler D., Taieb J., Hazout A., Frydman R. Premature elevation of plasma progesterone alters pregnancy rates of in vitro fertilization and embryo transfer. Fertil. Steril 1993; 59: 1090–4
   PubMed Web of Science ®Google Scholar